| London Stock Exchange: SKP
SkyePharma Plc delivers drug and develops oral and inhalation products. It develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The firm approves products in the areas of oral, inhalation and topical delivery. The company's products are marketed throughout the world by leading pharmaceutical companies. The company was founded by Ian Roderick Gowrie-Smith in 1996 and is headquartered in London, the United Kingdom.